Literature DB >> 1665400

Design and compliance of HBV vaccination trial on newborns to prevent hepatocellular carcinoma and 5-year results of its pilot study.

Z Sun1, Y Zhu, J Stjernsward, M Hilleman, R Collins, Y Zhen, C C Hsia, J Lu, F Huang, Z Ni.   

Abstract

A large-scale, controlled study of universal immunization of newborns against HBV infection has been conducted in the high incidence area of hepatocellular carcinoma, Qidong County of China. This area has a stable population, standardized cancer registration system, and an epidemiological base for measurements of liver cancer prevention by vaccine. Randomization was done on the community level. The vaccination and the control group each will consist of 38,000 children by the end of 1990. It is anticipated that the design will provide high statistical power to detect 50% reduction in the prevalence rate of chronic hepatitis among the vaccinees vs. the controls at 6 to 10 years of age, and 50% reduction in the incidence rate of hepatocellular carcinoma at 35 to 40 years of age. The vaccine used is Hep-B Vax, donated by Merck and Co. through WHO. The vaccine was administered at 0, 1, and 6 months after birth, the dosage of 5 or 2.5 micrograms in the pilot study as used before 1985 and of 5 micrograms dose level during the main study starting from January 1, 1985. About 85% of the cohorts have now entered the protocol. The vaccination coverage during 1984 to 1989 was 98.0% (35,064/35,789). Follow-up of the vaccinees and the age-matched controls at 5 years has exceeded 97%. The cumulative mortality in the vaccinated group up to 1988 was 1.29% (354/27,450). No single death nor serious adverse reaction was found that was associated with vaccination. The use of HBV vaccine at a reduced dose was especially important for the developing countries at the present time in order to achieve widespread immunization. Five-year results of the pilot study of this vaccination project showed that significant protection against HBV infection was achieved with the 5 or 2.5 micrograms per dose regimen plus a booster of 5 micrograms given at 3.5 to 4 years of age.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1665400

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  7 in total

1.  Evaluating the safety of new vaccines: summary of a workshop.

Authors:  Susan S Ellenberg; Mary A Foulkes; Karen Midthun; Karen L Goldenthal
Journal:  Am J Public Health       Date:  2005-05       Impact factor: 9.308

2.  TLR8 agonists stimulate newly recruited monocyte-derived cells into potent APCs that enhance HBsAg immunogenicity.

Authors:  Jun Du; Zhiyuan Wu; Shurong Ren; Yong Wei; Meihua Gao; Gwendalyn J Randolph; Chunfeng Qu
Journal:  Vaccine       Date:  2010-07-15       Impact factor: 3.641

Review 3.  Cancer burden and trends in the Asian Pacific Rim region.

Authors:  Binh H Yang; D Maxwell Parkin; Lin Cai; Zuo Feng Zhang
Journal:  Asian Pac J Cancer Prev       Date:  2004 Apr-Jun

4.  Identification of a novel liver-specific expressed gene, TCP10L, encoding a human leucine zipper protein with transcription inhibition activity.

Authors:  Zheng Chen; Long Yu; Hai Wu; Jianqiang Yu; Lisha Zhang; Daojun Jiang; Lijie Ma; Dan Li; Shouyuan Zhao
Journal:  J Hum Genet       Date:  2003-10-29       Impact factor: 3.172

5.  Efficacy of neonatal HBV vaccination on liver cancer and other liver diseases over 30-year follow-up of the Qidong hepatitis B intervention study: a cluster randomized controlled trial.

Authors:  Chunfeng Qu; Taoyang Chen; Chunsun Fan; Qimin Zhan; Yuting Wang; Jianhua Lu; Ling-ling Lu; Zhengping Ni; Fei Huang; Hongyu Yao; Jian Zhu; Jian Fan; Yuanrong Zhu; Zhiyuan Wu; Guoting Liu; Wenhong Gao; Mengya Zang; Dongmei Wang; Min Dai; Chu Chieh Hsia; Yawei Zhang; Zongtang Sun
Journal:  PLoS Med       Date:  2014-12-30       Impact factor: 11.069

Review 6.  Strategies for prevention of gastrointestinal cancers in developing countries: a systematic review.

Authors:  Ahmad Zia Shams; Ulrike Haug
Journal:  J Glob Health       Date:  2017-12       Impact factor: 4.413

7.  Host genetic factors and vaccine-induced immunity to hepatitis B virus infection.

Authors:  Branwen J Hennig; Katherine Fielding; John Broxholme; Mathurin Diatta; Maimuna Mendy; Catrin Moore; Andrew J Pollard; Pura Rayco-Solon; Giorgio Sirugo; Marianne A van der Sande; Pauline Waight; Hilton C Whittle; Syed M Zaman; Adrian V Hill; Andrew J Hall
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.